MARAbio Systems, Inc. is a precision immunology company with proprietary technology tied to a distinct cluster of maternal autoantibodies that cause Maternal Autoantibody Related Autism (MARA). The company holds exclusive rights to key discoveries by Dr. Judy Van de Water at UC Davis / MIND Institute that form MARA's biological basis. MARAbio has developed a proprietary blood test for women that can predict MARA prior to pregnancy and diagnose it in children as early as birth. The test is positioned to enable earlier behavioral intervention and treatment for children with MARA, a subtype estimated to comprise approximately 20% of individuals with autism and associated with more severe forms. MARAbio is also working to develop pre-symptomatic interventions and therapeutic treatments aimed at neutralizing the antibodies that cause MARA. The company intends to commercialize the test in 2025 and is pursuing development of therapeutic interventions alongside its diagnostic efforts.

Total raised

$19M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2024